Oncternal Therapeutics Revenue vs. Shares Owned By Institutions
| ONCTDelisted Stock | USD 0.53 0.00 0.00% |
For Oncternal Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oncternal Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oncternal Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oncternal Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oncternal Therapeutics over time as well as its relative position and ranking within its peers.
Oncternal |
Oncternal Therapeutics Shares Owned By Institutions vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Oncternal Therapeutics's current stock value. Our valuation model uses many indicators to compare Oncternal Therapeutics value to that of its competitors to determine the firm's financial worth. Oncternal Therapeutics is rated below average in revenue category among its peers. It is rated below average in shares owned by institutions category among its peers . The ratio of Revenue to Shares Owned By Institutions for Oncternal Therapeutics is about 65,037 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Oncternal Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Oncternal Revenue vs. Competition
Oncternal Therapeutics is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 145.16 Million. Oncternal Therapeutics maintains roughly 785,000 in revenue contributing less than 1% to equities under Health Care industry.
Oncternal Shares Owned By Institutions vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Oncternal Therapeutics |
| = | 785 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Oncternal Therapeutics |
| = | 12.07 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Oncternal Shares Owned By Institutions Comparison
Oncternal Therapeutics is currently under evaluation in shares owned by institutions category among its peers.
Oncternal Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Oncternal Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oncternal Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Oncternal Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Oncternal Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. Oncternal Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.
Oncternal Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Oncternal Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oncternal Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oncternal Therapeutics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Oncternal Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Suggestion Now
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios |
| All Next | Launch Module |
Use Investing Themes to Complement your Oncternal Therapeutics position
In addition to having Oncternal Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Wholesale Thematic Idea Now
Wholesale
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Wholesale theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Wholesale Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Oncternal Stock
If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |